
Medivir Q4 2024 - TTP Continues to Improve

Redeye reviews Medivir's fourth quarter report, which disclosed further improvements in patient survival. After the two recent equity issues, the company is well funded to continue developing fostrox towards a phase IIb trial.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Medivir Q4 2024 - TTP Continues to Improve](#)